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Strengths and limitations of this study
 ► The study uses a co- production design involving all 
stakeholders from the outset.
 ► The study is based on a strong theoretical 
underpinning.
 ► Psychoeducational programme is developed accord-
ing to the UK Medical Research Council guideline.
 ► A stand- alone package freely available from the 
internet.
 ► It was not possible to carry out a randomised con-
trolled trial to assess the effectiveness of the new 
intervention.
AbStrACt
Introduction Psychotropic medications that are primarily 
licenced for the treatment of psychiatric disorders are 
used widely (32%–85%) among people with intellectual 
disabilities (ID) often for the management of problem 
(challenging) behaviour in the absence of a psychiatric 
disorder. Care staff play a pivotal role in the prescribing 
process. Currently, no staff training programme exists 
to address the issue of overprescribing of psychotropic 
medication in people with ID, thus highlighting an urgent 
need for developing a psychoeducational programme (PEP) 
specifically designed to address this issue. We propose 
to develop a PEP for care staff using the methodology 
described in the UK Medical Research Council guide for 
complex interventions.
Methods and analysis The development of the PEP will 
involve (1) gathering information on available relevant 
training programmes, (2) running four focus groups with 
care staff and other professionals to establish the content 
and format of the PEP, and (3) organising a co- design 
event involving all relevant stakeholders to discuss the 
format of the PEP. A core project team will develop the PEP 
under guidance from the PEP Development Group which 
will consist of 10–12 relevant stakeholder representatives. 
Feedback from selected stakeholders on a draft PEP will 
allow us to refine the PEP before implementation. The PEP 
will have web- based modules supplemented by face to 
face training sessions. When the final draft is ready, we will 
field test the PEP on six to eight care staff from community 
care homes for people with ID. After completing the field 
test, we will run a focus group involving participants in the 
PEP to get feedback on the PEP.
Ethics and dissemination Ethics approval for this study 
was waived by the UK Health Regulatory Authority as the 
study does not collect any patient related information and 
only include care staff outside the UK NHS. This will be the 
first ever such universally freely available PEP supported 
by training manual and slides.
IntroduCtIon
Psychotropic medications are used widely 
(32%–85%; average 49%–63%) among 
people with intellectual (learning) disabil-
ities (ID).1 2 Many people with ID are also 
prescribed additional medication for coex-
isting physical health problems.3 Psychotropic 
medications are used for both to treat mental 
illness and also used, off licence, for problem 
(challenging) behaviour such as aggression.4 
Problem behaviours are more common in 
people with ID than in the non- ID general 
population.5 In a previous study, Clarke and 
colleagues found that 36% of those who 
received psychotropic medication did not 
have a psychiatric diagnosis.6 A recent general 
practitioner (GP) register based study in the 
UK has shown that “of 9135 peoples treated 
with antipsychotic drugs, 6503 (71%) did not 
have a record of severe mental illness.2 Of the 
11 915 with a record of challenging behaviour, 
5562 (47%) had received antipsychotic 
drugs. Of those with a record of prescription 
of antipsychotics, 2362 (26%) did not have a 
record of severe mental illness or challenging 
behaviour.” In the UK, the National Insti-
tute for Health and Care Excellence (NICE) 
recommends non- pharmacological interven-
tion in the first instance for the management 
of problem behaviour in people with ID.7
Off- licence use of psychotropic medication 
in people with ID is a public health concern 
because of lack of evidence demonstrating 
their effectiveness in treating problem 
behaviour in the absence of a diagnosed 
psychiatric diagnosis,8 the high rate of adverse 
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Table 1 Types of training currently available for staff who support people with intellectual disabilities
Proactive training Reactive training Responsive training
 ► Person centred values and attitudes training
 ► Increasing knowledge
 ► Training on the communicative aspects of 
challenging behaviour
 ► Training on attributions of challenging behaviour
 ► Training on emotional intelligence
 ► Training on risk assessment/risk management 
culture
 ► Appropriate physical skills 
training
 ► Nidotherapy
 ► Behavioural skills training
 ► Incident analysis
 ► Formulation
Proactive support Reactive support Responsive support
 ► Reflective practice groups
 ► Supervision
 ► Stress management processes
 ► Post incident support  ► Individual support (formal and informal)
 ► Psychological support
effects which can be difficult to assess9 and difficulty in 
withdrawing people from some medications.10 Because 
of these concerns, NHS England in the UK launched 
a major initiative called ‘Stopping Over- Medication 
of People with a Learning Disability, Autism or Both’ 
(STOMP).11 STOMP aims to prevent inappropriate use 
of medication for people with ID. However, this initiative 
does not address the important role that staff carers of 
people with ID might play in efforts to reduce the use of 
psychotropic medication.
In a previous study, we found only a few carers (both 
paid and family carers) explicitly reflected on how their 
own behaviour may influence aggressive behaviour in 
a person with ID.12 Carers felt that they would benefit 
from information and training on the role that they and 
the wider environment may play in triggering problem 
behaviour. Another recent qualitative interview study of 
ours has shown that many professionals and family carers 
feel that care staff need more knowledge and training in 
the use of medication for the management of problem 
behaviour in people with ID.13
A recent review has found that a number of small 
studies of staff training under ‘proactive’, ‘reactive’ and 
‘supportive’ training framework have shown improved 
management of problem behaviour in people with ID (see 
table 1).14 However, none of these training programmes 
is specifically designed to reduce overuse of psycho-
tropic medication. A recent Cochrane review found four 
randomised controlled trials (RCTs) of psychoeduca-
tional programme (PEP) directed to care staff to reduce 
antipsychotic use to manage challenging behaviour in 
people with dementia.15 All studies showed a reduction in 
antipsychotic use at end point.
A properly designed PEP should increase care staff 
knowledge and understanding of the issues and support 
a positive attitude towards managing problem behaviour 
using alternatives to medication. This should subse-
quently help to reduce overmedication of people with ID. 
This in turn has the potential to improve the quality of 
life of people with ID. We, therefore, propose to develop 
a PEP for paid care staff which will follow the principles 
laid down in the International Guide for the use of medi-
cation to manage challenging behaviour in adults with 
ID.16
Study aims and objectives
The overall study aim is to undertake pretrial devel-
opment and testing of a PEP which has the potential 
to reduce overprescribing of psychotropic medication 
among people with ID by informing, empowering and 
equipping care staff with the skills they need to better 
understand problem behaviour, manage their psycholog-
ical responses to it and negotiate alternative strategies for 
reducing problem behaviour without an over reliance on 
the use of psychotropic medication.
The specific research objectives are as follows:
1. To develop a PEP for care staff in community settings 
to help reduce the overuse of psychotropic medication 
among adults with ID.
2. To carry out a field testing of the PEP in preparation 
for a future RCT.
3. To conduct a process evaluation to gather feedback 
from participants in the PEP training to assess imple-
mentation issues.
MEthodS
We will develop the PEP according to Medical Research 
Council (MRC) guideline for the development and eval-
uation of complex intervention (see table 2).17 18 This will 
involve a PEP developmental phase using a collaborative 
co- production approach followed by field testing with 
embedded process evaluation.
theoretical framework
We will apply the model of ‘The Theory of Planned 
behaviour’ (TPB) while developing the PEP.19 This theory 
links one's beliefs with behaviour. According to this theory, 
human behaviour is guided by three kinds of consider-
ation, ‘behavioural beliefs’ (what the person believes), 
‘normative beliefs’ (expected beliefs) and ‘control 
beliefs’ (outside factors controlling their beliefs). In our 
study, various aspects of care staff’s beliefs will be explored 
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Table 2 Framework for the development and evaluation of complex interventions (MRC guide)
Phases MRC recommended methods Our proposed method
1. Preclinical/theoretical Review relevant theory and evidence to 
ensure (1) best choice of intervention, and 
(2) predict major confounders and strategic 
design issues
Collating information from:
Systematic review of PEPs in neurodevelopmental 
disorders (underway)
Current e- modules available for treatment in various 
psychiatric disorders such as schizophrenia, bipolar 
disorder, anxiety disorder and so on.
Outcome of the STOMP initiative, and other e- modules 
and training programmes for care staff in the field of ID
2. Modelling Identify (1) intervention components, and 
(2) how intervention components interrelate 
and relate to surrogate or final health 
outcomes
Co- development of PEP with stakeholders (through 
focus groups and co- design event) to identify the 
targets for the intervention (and their relation to health 
outcomes), its components (content) and model(s) of 
delivery
3(a). Operationalisation Describe components of a replicable 
intervention
Formalising of action plans developed in the co- design 
event by the PEP Development Group to finalise the 
content and delivery of the PEP
3(b). Piloting exploratory 
trials
Describe a feasible trial protocol for 
comparing the intervention to an 
appropriate alternative
Instead of a full feasibility study we are now proposing 
an initial field testing and refinement of the PEP
4. Definitive RCT Compare a fully defined theory- based 
intervention to an appropriate alternative, 
using a protocol that is reproducible and 
adequately controlled in a study with 
appropriate statistical power
We intend to apply for funding for a future definitive 
RCT using cluster randomisation methods in 
community care homes for people with ID with a built- 
in pilot study
5. Long- term 
implementation and 
monitoring
Determine whether the intervention 
and results can be reliably replicated in 
uncontrolled settings over the long term
Should be future work after the proposed RCT results 
become available
ID, intellectual disabilities; MRC, Medical Research Council; PEP, psychoeducational programme; RCT, randomised controlled trial.
and the project will try to influence beliefs in order to 
encourage positive behaviour, which will be measured by 
assessing care staff’s beliefs, particularly controllability of 
and attribution to the problem behaviour.
Crucially, behavioural change interventions (eg, 
training care staff) may only work on improving knowl-
edge, without paying attention to the other factors which 
limits the potential for change as it is only targeting one 
area (eg, capacity). Motivation is often overlooked and 
relates to attitudes/attributes/beliefs. The TPB frame-
work will be integrated both within the development of 
the training package and the evaluation of the package 
through Process Evaluation (see later).
Study setting and participants
The following groups have been identified as stakeholders:
 ► Adults with ID.
 ► Their families.
 ► Care staff working with people with ID and managers 
of services.
 ► Community Learning Disability Team members.
 ► General practitioners and pharmacists.
 ► Service provider organisations.
We will involve all stakeholders in the development 
of the PEP. Stakeholders will be identified for participa-
tion in all stages of the project through care provider 
organisations such as Achieve Together (formerly CMG), 
Dimensions- UK, and Voluntary Organisations Disability 
Group (VODG) (an umbrella organisation of social care 
service provider organisations in the UK), Challenging 
Behaviour Foundation (CBF; a family carer organisation), 
and project group members’ contacts. The Director of 
Quality and Clinical Care in Achieve Together (a service 
provider organisation for people with ID) is also a project 
group member.
The project will be carried out under three phases.
Phase I: development of the PEP
Phase I is broken down into the following components;
a. Collate information on existing training programme 
to avoid unnecessary duplication.
b. Focus groups to establish stakeholders’ views and pref-
erences on the content and format of the PEP.
c. Co- design event to bring together stakeholders to dis-
cuss the content and the format of the PEP.
d. PEP Development Group meetings.
e. Feedback from selected stakeholders on a draft PEP 
outline.
We will use Experience- based co- design (EBCD) 
method to develop the PEP.20 EBCD is a collaborative 
approach that aims to improve healthcare services by 
enabling service- users, carers and staff (ground- level 
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and management) to collaborate together to co- design 
better services. The approach draws on participatory 
action research, user- centred design, learning theory and 
narrative- based approaches to change.21 It was first piloted 
in a Head and Neck Cancer service,22 and subsequently a 
toolkit was developed by the King’s Fund.23 Its distinctive 
features are that it is evidence- based, that it uses people’s 
experiences for that evidence and that it involves close and 
equal collaboration among all the groups of people who 
may have a stake in the system or process which is to be 
improved.
We will set up a PEP Development Group (PEP- DG) 
(10–12 people) comprising all the stakeholder groups’ 
representatives mentioned earlier. The group will meet 
three times. The first meeting will set the scene and decide 
on the terms of reference. The group will then meet after 
information gathering on existing training programmes 
and focus groups to discuss the results and set up the 
co- design event. In the third meeting, after the co- design 
event, the outline for the PEP will be confirmed.
A core research team consisting of the principal inves-
tigator, the researcher and some key project group 
members will liaise regularly to develop the PEP compo-
nents under the PEP- DG’s guidance. We expect the PEP 
modules to be based on (1) behaviour principles, (2) 
different behaviour management techniques, (3) role 
playing/case- based discussion, (4) homework assign-
ments, and (5) review and feedback.24 In order to make 
the intervention replicable, we will develop a manual 
along with slides, and videos of case vignettes. The 
manual will clearly describe tasks for each session, train-
er’s scripts and other training material such as workbook, 
activity sheet, videos and homework tasks, as well as data 
collection form.
The PEP will be developed using a reiterative process of 
core research group initially producing different modules 
through regular meetings among them and by collating 
information from various sources such as the information 
gathered on existing training programmes, from focus 
groups and co- design event discussions but also guided 
by regular feedback received from the PEP- DG to fine- 
tune the materials.
Qualitative work (focus groups)
Qualitative research in phase I of the study will involve 
focus groups with key stakeholders. An interview schedule 
will be developed that can be employed flexibly and be 
open to emergent themes but framed using the Theory 
of Planned behaviour, thus examining beliefs and atti-
tudes (eg, about psychotropic medication and alternative 
approaches such as positive behavioural support) and 
how these might influence behaviour (eg, in terms of 
requesting support from professionals to prescribe medi-
cation or provide help with alternative approaches).
As this is primarily a qualitative research, the sample 
will be recruited purposively. Voluntary, informed consent 
will be obtained from all participants before focus group 
interviews. We will retain the contact details until the end 
of the study of those who would like to receive a final 
summary report. Participants will also be invited to take 
part in the co- design event.
The sample size is a pragmatic decision. No formal 
sample size calculation is required for this study. This is a 
small study with limited resources and includes primarily 
qualitative data collection. The minimum sample size 
we are aiming for is 8–10 care staff in each focus group 
(there will be two separate focus groups) and 6–8 care 
staff for the field testing of the PEP.
We will conduct four focus groups: two with care staff 
only and two with service managers, trainers/learning 
heads of service provider organisations and CLDT 
members. Participants will be purposively sampled for 
each group to include a range of care staff from different 
community settings. A researcher with previous expe-
rience of conducting qualitative research will run the 
focus groups under supervision of an expert in quali-
tative research (TW). We will use the approach used in 
our previous studies of interviewing carers of people with 
ID as well as head injury.25 26 The first two focus groups 
involving care staff and the service mangers and other 
stakeholders respectively will explore issues around 
medication use, and assessment and management of 
challenging behaviour. The second two focus groups will 
explore carers’ and other stakeholders’ views respectively 
on what should be the content and format of the PEP 
considering what training is already available and where 
the gaps are. Focus group discussions will be semistruc-
tured using a topic guide, audio recorded and transcribed 
verbatim.
NVivo computer software will be used to manage data 
and support analysis.27 After familiarisation with the 
data (reading transcripts), an initial coding frame will 
be developed built on both a priori research questions 
and themes developed in the data. This coding frame will 
be refined as data collection and analysis progress. The 
framework to the data (indexing) will be applied with 
the aim of allocating all data to a theme (either already 
defined or emergent at this point). At the analytical stage, 
constant comparison will be used to discern patterns and 
divergences in the data and to support the identification 
of concepts and categories that enable a comprehensive 
and detailed response to the research questions.28 Trian-
gulation will be used on a selected sample of transcripts to 
maintain inter- rater reliability of data analysis.
Co-design event
A 1- day conference of carers and other stakeholders 
(about 20–30 people) will be organised to further develop 
the PEP using EBCD model. At the event, facilitators from 
the core research team will prepare small groups of four 
to five people for working together by establishing expec-
tations for the day, identifying group rules, describing 
available support (quiet spaces, ‘floating’ facilitators) 
and doing some ‘icebreaking’. The core project team will 
present the content themes for the PEP and if possible, 
a short 2 min video of an interview with a person with ID 
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who receives medication for problem behaviour will be 
presented at the outset. Then each group will work on 
developing an action plan to address their priority area. 
The action planning process will follow a clear structure 
and should produce a plan which will identify: the outline 
of what should be included in each module, what format 
this should take, and how to deliver this, and have a clear 
outline of who will do what by when. Each group will be 
given specific tasks of planning how best to address issues 
such as (1) the format of the PEP such as web- based, 
self- guided learning, group training sessions, modular 
contents with hyperlinks, passive or active learning and 
so on; and (2) content and format of face- to- face training 
sessions. The core research group will then collate the 
action plans to develop the first draft of the PEP which 
will be presented to the PEP- DG.
Wider stakeholder consultation
An outline of the draft PEP will be circulated (either 
by post or by email where possible) widely to a varied 
group of stakeholders for feedback (approximately 20–30 
people and organisations). Once the wider stakeholder 
feedback is received, the PEP will be finalised for field 
testing. The feedback will be studied by the core research 
group who will take advice from the PEP- DG on those 
feedback.
Intervention
The PEP will equip care staff with the skills and the 
support to work with people with ID and health profes-
sionals in a proactive way to avoid over- reliance on medi-
cation and to seek alternatives for the management 
of problem behaviour. The intervention will have two 
components: (1) an educational component comprising 
web- based information material including video- based 
case studies, and (2) face- to- face training sessions. We 
envisage that the e- learning will be developed under the 
following broad headings; (1) information about medi-
cation, their indications and adverse effects; (2) causes 
and effects of problem behaviours and their assessment; 
(3) non- pharmacological management strategies for 
problem behaviour; and (4) advice about work- related 
stress management. Face- to- face training will provide (1) 
information- based discussion using the e- learning mate-
rial and solution focused case studies but also (2) direct 
support for the care staff such as mindfulness training to 
reduce stress of carer burden and improve psychological 
mindedness.
The ultimate format and content (and the method of 
delivery, eg, number of sessions, group size, frequency, 
duration of sessions) of the PEP will be established 
in phase I and after the initial field testing. The web- 
based information is likely to be modular in nature so 
that this could apply to carers in different settings and 
cover medical, psychological and social/environmental 
causes and management of behaviour. The programme 
will encourage care staff to use a holistic, person- centred 
approach to behaviour management, highlighting 
alternatives to medication and considering functional 
determinants of behaviour. This will follow the principles 
laid down in our International Guide16 and will align with 
the UK NICE recommendations for interventions for 
problem behaviour in people with ID.7
Phase II: field testing
Setting and eligibility criteria
For field testing, six to eight care staff will be recruited 
from different group homes in London through more 
than one service provider organisations. The PEP will be 
delivered in the preferred presentation format as deter-
mined by the development process in phase I. We have 
a commitment to deliver face to face training in as few 
sessions as possible. Based on the feedback from the field 
testing, we will finalise the optimum number of sessions 
and the format required for a future definitive RCT.
Inclusion criteria
 ► Care staff working with adults with ID within service 
provider organisations within a community setting.
Exclusion criteria
 ► Care staff working solely with children and within a 
hospital setting.
Outcome measures
The following carer- related measures will be used prior to 
the training sessions and at the end.
Two questionnaires will be used to assess care staff’s 
knowledge of medication use (Knowledge of Psycho-
tropic drugs Questionnaire29) and attitude towards 
management of behaviour (attribution) in general and 
drug use in particular (Management of Aggression and 
Violence Attitude Scale- Revised- adapted for ID) (MAVAS- 
R- ID).30 We will assess carer’s quality of life (QoL) using 
SF-36,31 EQ- 5D- 5L,32 mental state using Hospital Anxiety 
and Depression Scale (HADS),33 and Carer Well- being 
and Support Questionnaire (CWSQ).34
Data analysis
We will not analyse any carer- related outcome data, but 
they will be used to assess the feasibility of data collection 
using these specific measures. Therefore, this study will 
not involve any statistical data analysis.
Phase III: process evaluation
We will run a focus group of the participants who took 
part in the training to explore their experience of partic-
ipating in the study and changes that could be made to 
ensure that a subsequent definitive trial was acceptable. 
We will explore participant’s beliefs about the impact of 
this intervention (including both positive and negative 
effects), mechanisms of action and factors that facili-
tate or hinder its successful delivery. These will be audio 
recorded and transcribed. Data will be professionally 
transcribed and subjected to thematic analysis aided by 
NVivo software.35 The same methodology will be used 
as in phase I qualitative study. We shall collect data from 
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the participants on the PEP’s applicability, acceptability, 
practicality and relevance using an adapted version of the 
Feasibility scale devised by Zeilinger and colleagues for 
carers of adults with ID.36
As this is primarily a qualitative research, the sample will 
be recruited purposively. This will involve recruiting care 
staff from different organisations, different geographical 
localities and different care settings. Voluntary, informed 
consent will be obtained from all participants before focus 
group interviews. We will retain the contact details until 
the end of the study of those who would like to receive a 
final summary report.
Project management
We will set up a project management group which 
will meet every 4 months (some meetings will be held 
through teleconference). Additionally, the core research 
group will meet every 3–4 weeks and will liaise regularly 
with the project management group and the PEP- DG. 
We will set up a combined steering and data manage-
ment committee including independent experts and 
carers who will oversee the project governance and data 
management. They will meet every 7 months and the 
core research team will report to them. Care staff and 
people with ID (including advocates) advisory groups will 
provide regular feedback to the project group.
Project timetable
Start 01.04.2019; duration 18 months. Set up: 1 month; 
Development of the PEP (phase I): 11 months; Field 
testing of the PEP and process evaluation (phase II+III): 
3 months; Writing reports, papers, HTA application draft 
for a future definitive RCT: 3 months. Original estimated 
study end date was 30 September 2020, which may now be 
delayed because of COVID-19 pandemic.
dISCuSSIon
Every day in England, psychotropic medication is given 
inappropriately to up to 35000 people with ID, at an esti-
mated cost to the UK NHS of c.£14 million.37 In addition, 
the quality of life of patients and carers will be impacted 
by adverse effects, premature mortality, the increased 
burden on family carers (including loss of income), all 
of which incur further health and societal costs. Hence, 
the overmedication of people with ID, particularly the use 
of psychotropic medications for problem (challenging) 
behaviour in the absence of a diagnosed psychiatric 
disorder, is a major public health concern in the UK and 
worldwide.
Care staff play a pivotal role in influencing these 
prescribing decisions as they know the person with ID best 
and are supposed to represent the best interests of the 
person they support. Our proposal to develop a training 
programme specifically geared at care staff is relevant to 
the burden of disease priorities and needs of the UK NHS. 
NHS England has launched a major initiative to address 
this concern called ‘Stopping Over- Medication of People 
with a Learning Disability, Autism or Both’ (STOMP).11 
However, the STOMP programme has not involved devel-
opment of any structured training programme for care 
staff. By addressing this critical training need, our work 
will complement the STOMP initiative and fill in an 
important gap in the NHS policy framework.
The PEP will not only address knowledge gap among 
the care staff but also help to develop a positive attitude 
towards the management of problem behaviour, particu-
larly exploring staff reaction to problem behaviour and 
how best to address them by understanding the person 
behind the behaviour. We will do this by following MRC, 
UK guideline development recommendation. Therefore, 
we will set up a PEP- DG involving all stakeholders’ repre-
sentatives and will involve all stakeholders from the outset 
using a co- production model. The PEP will have a web- 
based module complemented by a face to face training 
session. We will carry out a field testing of the PEP and 
also conduct a process evaluation to gather feedback 
from participants in the PEP training to assess implemen-
tation issues in preparation for a future RCT.
Our PEP will be first ever universally available package 
freely available for use anywhere in the world. If useful, 
similar models could be used for PEPs in relation to other 
disorders and health issues where reduction of medicine 
use is desirable such as schizophrenia.
Our PEP will be based on a strong theoretical back-
ground as this is designed not only to provide knowledge 
but more importantly to change care staff attitude to 
empower them which may be a critical mechanism for 
helping with the reduction in over- reliance in medica-
tion in addressing problem behaviour in people with ID 
as overmedication of people with ID is contrary to NICE 
recommendation.7 Another strength of our PEP is that 
this will be case vignette based, so the care staff could 
relate the training with their day to day practice and 
implement them. The PEP will be stand alone because it 
will be accompanied by training manual and designed to 
be accessible to those who have not attended the accom-
panying face to face training session. Therefore, anyone 
anywhere in the world can access the training material 
and use them without any prior training for themselves. 
Similarly, the care staff could access the training mate-
rial directly to help themselves. Although the PEP will be 
developed keeping primarily care staff in mind, but this 
PEP could be useful to other stakeholders such as family 
carers and nurses, occupational therapists, speech and 
language therapists, pharmacists, GPs and even service 
providers and commissioners.
We will use a co- production model using the EBCD 
procedure which involves all the stakeholders from the 
outset. This will make the PEP both evidence- based, but 
also consensus- based. This should make the PEP accept-
able to care staff for whom the programme is designed. 
This will also provide good face validity to the intervention.
The efficacy of the PEP will not be assessed in this 
study, but we intend to design and conduct an appropri-
ately designed RCT to address this question in the future. 
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The outcome measures only assess care staff knowledge 
and attitude which is at the core of the PEP but it is not 
within the remit of this project to collect any data related 
to people with ID who are supported by the care staff who 
will take part in the project. Also given the resource avail-
able, we will be able only to measure short- term outcome 
related to care staff knowledge and attitude.
PAtIEnt And PublIC InvolvEMEnt
The application has been developed jointly with the key 
stakeholders, namely people with ID, their family carers 
and care staff. We have also had input from a GP, a phar-
macist, a clinical psychologist and community learning 
disability team members. Two parents and one director 
of a provider organisation representing care staff are 
members of the project team.
A number of family carers provided feedback through 
the family carer organisation, Challenging Behaviour 
Foundation (CBF). We have also received a large number 
of comments from care staff. All the relevant stakeholders 
will remain fully involved all throughout the project. We 
will set up two advisory groups, one comprising four 
care staff and another four adults with ID. These groups 
will meet every 4 months and will provide feedback and 
advice throughout the project and co- design topic guides 
for interviews. The advisory groups will also advise on 
accessible information leaflets and web- based newsletters 
for the project.
EthICS And dISSEMInAtIon
Ethics approval for this study was waived by the UK Health 
Regulatory Authority as the study does not collect any 
patient- related information and only include care staff 
outside the UK NHS. People with ID are involved as stake-
holders and will act in an advisory capacity only. Consent 
to enter the study will be sought from each participant 
only after a full explanation has been given, an informa-
tion leaflet offered and time allowed for consideration. 
Signed participant consent will be obtained. The right 
of the participant to refuse to participate without giving 
reasons will be respected. All participants are free to with-
draw at any time.
The project will produce a PEP for care staff with 
accompanying manual and workbooks. Dissemination 
will be ongoing. A project website at Imperial College 
London hyperlinked with the Royal College of Psychia-
trists (professional organisation), MENCAP (carer organ-
isation), VODG and CBF, will host relevant information. 
A newsletter will be distributed twice a year to update 
interested parties on the progress of the project and the 
findings of each stage. Careful attention will be paid to 
providing accessible information for people with ID and 
their carers. Accessible newsletters will be distributed via 
service user organisations and the final guides and reports 
will be available in accessible format.
We will run a dissemination workshop at the end of 
the project involving stakeholders and service provider 
organisations. This event will be free to attend and open 
to a wide range of delegates. We will disseminate the find-
ings in VODG (an umbrella organisation for disability 
service providers in the community) and the Royal 
College of Psychiatrists’ conferences. A summary report 
will be produced and sent to a wide range of stakeholders. 
Papers will be prepared for publication in high- impact 
peer- reviewed academic journals (including open access 
journals) as well as professional journals to target a wide 
audience. Findings of the study will also be presented in 
local, national and international meetings and confer-
ences. All the documents prepared throughout the 
project will be made available on the project website and 
be widely and freely available.
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